Obesity has traditionally been defined as a body mass index (BMI) of 30 kg/m 2 or more. However, BMI has limitations, and obesity is now defined by a number of factors, including waist circumference.
US ENDOCRINOLOGY
In addition to life-threatening adverse health consequences, obesity also increases the likelihood of disabling conditions such as osteoarthritis, 16, 17 benign prostate hypertrophy, 18 infertility, 19 asthma, 20, 21 and obstructive sleep apnea; approximately 70 % of patients with the latter condition are obese. 22 Obesity has also been implicated in anatomical changes that predispose patients to upper airway obstruction and reduced neuromuscular control of the air passages during sleep. 23, 24 Obesity accelerates the initial onset and progression of physical disability in older adults. 25 Maternal obesity is associated with an increased risk for congenital anomalies. 26 The early onset of obesity compounds the health burden. Since obesity is prevalent at a much younger age than in previous generations, recent projections suggest a growth in the proportion of the population living with chronic disabilities and a potential threat to the continued increase in life expectancy achieved by medical and public health advances during the past century. 27 The chronic and acute health consequences of obesity present a considerable burden to society, not only by impairing health-related quality of life, 28 but also because of the economic impact, a result of increased healthcare costs, and lost productivity. 29 Compared with normal-weight individuals, obese patients incur 46 % increased inpatient costs, 27 % more physician visits and outpatient costs, and 80 % more spending on prescription drugs. 29 Projections suggest that there will be 65 million more obese adults in the US by 2030 (see Figure 1 ), resulting in an additional 6-8.5 million cases of diabetes, 5.7-7.3 million cases of heart disease and stroke, 492,000-669,000 additional cases of cancer, and 26-55 million lost quality-adjusted life years for the US and UK combined. This is associated with an increased medical expenditure of $48-66 billion/year in the US. 30 Another model suggests that by 2030, 42 % of the population will be obese, with the prevalence of severe obesity predicted to be 11 %. This report states that, if obesity were to remain at 2010 levels, the combined savings in medical expenditure over the next 2 decades would be $549.5 billion. 31 There is clearly a need for clinical intervention to tackle the obesity epidemic. Modest weight loss (2.6-4.9 kg) is associated with improvements in weight-related comorbidities [32] [33] [34] and greater benefits are seen with increased weight loss. 35 A recent report suggested that healthcare systems could make substantial cost savings through anti-obesity medications that promote weight loss, and consequently reduce the progression to type 2 diabetes, and improve blood pressure (BP 
Treatment of Obesity
The National Institutes of Health (NIH) National Heart, Lung, and Blood
Institute (NHLBI) recommends that the initial goal of weight-loss therapy in overweight and obese individuals should be to reduce bodyweight (BW) by 10 % from baseline. 37 The mainstay of obesity treatment is lifestyle modification, which consists of reductions in caloric intake (by 500-1,000
calories per day), increases in physical activity, and changes in health behaviors. However, only 15-20 % of patients successfully achieve and maintain a 5 % weight loss at 1 year. 38, 39 Given the frustrations doctors and patients face in achieving results by use of diet and exercise, pharmacologic therapies, or bariatric surgery are also viable options for patients meeting eligibility criteria. 40 The indication for bariatric surgery is restricted to those with severe obesity (BMI ≥35 kg/m 2 ) owing to the risks associated with invasive procedures, 41, 42 although laparoscopic gastric banding may be considered for patients with BMI ≥30 kg/m 2 with one or more adverse health consequences due to excessive body fat. Both phentermine and topiramate are approved by the FDA as monotherapy, with different indications. Phentermine is a sympathomimetic amine and was approved (at a dose of up to 37.5 mg/day) as a short-term obesity treatment by the FDA in 1959. 57 Although its exact mechanism of action is unknown, its effect on weight management is likely mediated by the release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption; other metabolic effects may also be involved. 58 Topiramate, a fructose monosaccharide with sulfamate Figure 2) .
Obese patients treated with PHEN/TPM ER also showed a significant reduction in obesity-related adverse health consequences. In the EQUIP and SEQUEL studies, the PHEN/TPM ER 15/92 mg group had significantly greater improvements in systolic and diastolic BP, fasting glucose, triglycerides, total cholesterol, low-density lipoprotein (LDL), and highdensity lipoprotein (HDL) compared with placebo (see Figure 3) . 64, 67 In the CONQUER study, significant improvements were reported in BP, waist circumference, and concentrations of lipid, fasting insulin, glycemic, and inflammatory biomarkers in the PHEN/TPM ER groups compared with placebo. 66 Cardiometabolic risk factors improved significantly in the PHEN/ TPM ER groups, with significant reductions in BP, particularly in patients with hypertension at baseline, and in triglycerides, high-sensitivity C-reactive protein, and total cholesterol, 66 in patients with dyslipidemia at baseline. 68 In the CONQUER study, in patients with hypertension, changes in systolic BP were -9.1 mm Hg, -6.9 mm Hg, and -4.9 mm Hg, respectively, in the and a positive, significant (p=0.0003) correlation between percent change in weight and change in apnea-hypopnea index. Significant improvements in overnight oxygen saturation and reduction in BP compared with placebo were also reported.
Safety Data for Phentermine/ Topiramate Extended-release
Common AEs were consistent across the wide range of patient populations studied in the EQUIP, CONQUER, and SEQUEL studies. Paresthesia, dry mouth, and constipation (up to 21 % in the 15/92 mg groups) were reported most frequently, with insomnia, dizziness, and dyseusia in less than 13 % of participants. 64, 66, 67 In the CONQUER study, dose-related trends were noted for rates of dry mouth, constipation, dysgeusia, paresthesia, insomnia, dizziness, irritability, and disturbance in attention. 66 Depression-related symptoms were also reported in 7 % and anxiety-related symptoms in 8 % of the highest-dose subjects, respectively. A small increase in heart rate was seen in the CONQUER trial: 0.1 beats per minute in the 7.5/46 mg group and 1.7 beats per minute with 15/92 mg. 66 Potentially serious safety concerns regarding PHEN/TPM ER include teratogenicity. Data from the North American AED and Pregnancy
Registry (NAAPR) showed a 10 times higher-than-expected incidence in women treated with topiramate during pregnancy. 72 Data from the Slone
Epidemiology Center Birth Defects Study (BDS) and the Center for Disease
Control's National Birth Defects Prevention Study (NBDPS) suggest that first trimester topiramate exposure may confer an increased risk for oral clefts with a combined odds ratio of 5.4 (95 % CI 1.5-20.1). 73 However, a more recent population-based cohort study of 837,795 liveborn infants in Denmark did not find an increased incidence of birth defectsthe adjusted prevalence odds ratio (OR) for major malformations in infants exposed to topiramate during pregnancy compared with infants not exposed to any antiepileptic drug was 1.44 (95 % CI 0.58-3.58). 74 There are no restrictions on the use of PHEN/TPM ER in women of childbearing age; however, it is recommended that patients be counseled on pregnancy avoidance, effective contraception is utilized, and testing is encouraged to detect early pregnancy. The FDA has required a Risk Evaluation and Mitigation Strategy (REMS) in order to inform clinicians and females of reproductive potential about these safety concerns. 75 There has been concern about the association of obesity drugs with cardiac valvulopathy, 76 which led to the withdrawal of the weight-loss drugs fenfluramine and dexfenfluramine. This effect was driven by offtarget effects of these two serotonergic drugs on the 5-hydroxytryptamine receptor 2B receptor (5-HT 2B ) on the heart. Neither phentermine nor topiramate has any serotonergic activity. Echocardiographic studies in humans support the assertion that phentermine is not causally related to valvulopathy. 77 Additionally, a population-based study evaluating the risk for newly diagnosed idiopathic valvular disease in patients using dexfenfluramine, fenfluramine, or phentermine as an appetite suppressant found no cases of cardiac-valve abnormalities among those who took phentermine alone. 78 In a phase II trial, echocardiographic changes were evaluated in 100 patients who received phentermine alone or phentermine in combination with topiramate, and found no treatment-emergent valvular heart disease. than 3 % of BW) are either discontinued or undergo a parallel two-step titration to the 15/92 mg dose. 80 Such an algorithm should ensure that only patients who truly benefit remain on therapy, and can be maintained at a dose level that maximizes individual patient benefit:risk.
Summary and Concluding Remarks
The declaration of obesity as a disease may help to direct more serious attention to this condition by patients and providers. It must be stressed that the most effective tool to tackle the obesity epidemic is prevention: treatment alone will fail in the setting of this epidemic. The coverage of antiobesity medication by health insurance companies has limited their use. However, the well-documented and substantial health and healthcare implications of obesity give great urgency to the need for safe and effective long-term pharmacologic treatment to complement lifestyle modifications.
Prior to the approval of PHEN/TPM ER, available anti-obesity therapies generally offered efficacy of 5 to 6 % BW loss. 81, 82 Clinical trial data show that PHEN/TPM ER, together with a modest lifestyle intervention, was generally well-tolerated and resulted in robust, dose-related weight loss that was maintained for more than 2 years.
PHEN/TPM ER was also associated with improvement in adverse health consequences of obesity, including the most common weight-related comorbidities of hyperglycemia, dyslipidemia, and hypertension, in conjunction with reduced use of concurrent medications. In conclusion, PHEN/TPM ER, with lifestyle modification, represents a valuable new agent in the treatment armamentarium to counteract increasing rates of obesity and obesity-related adverse health consequences. n
